warnings
WARNINGS In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids, including Dexamethasone Elixir, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteriods can: Reduce resistance to new infections Exacerbate existing infections Increase the risk of disseminated infections Incease the risk of reactivation or exacerbation of latent infections Mask some signs of infection Corticosteriod-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteriod dosages. Monitor for the development of infection and consider Dexamethasone Elixir withdrawal or dosage reduction as needed. Tuberculosis If Dexamethasone Elixir is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged Dexamethasone Elixir therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteriods, including Dexamethasone Elixir. In corticosteriod-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles: If a Dexamethasone Elixir-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered. If a Dexamethasone Elixir-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated. Hepatitis B Virus Reactivation Hepatitis B Virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteriods, including Dexamethasone Elixir. Reactivation can also occur infrequently in corticosteriod-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before intiating immunosuppressive (e.g., prolonged) treatment with Dexamethasone Elixir. For patients who show evidence of hepatitis B infection, recommend consultation with physcians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy. Fungal Infections Corticosteriods, including Dexamethasone Elixir, may exacerbate systemic fungal infections; therefore, avoid Dexamethasone Elixir use in the presence of such infections unless Dexamethasone Elixir is needed to control drug reactions. For patients on chronic Dexamethasone Elixir therapy who develop systemic fungal infections, Dexamethasone Elixir withdrawal or dosage reduction is recommended. Amebiasis Corticosteriods , including Dexamethasone Elixir, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before intiating Dexamethasone Elixir in patients who have spent time in the tropics or patients with unexplained diarrhea. Strongyloides Infestation Corticosteriods, including Dexamethasone Elixir, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, cortcosteriod-induced immunosupression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Cerebral Malaria Avoid corticosteriods, including Dexamethasone Elixir, in patients with cerebral malaria. Kaposi's Sarcoma Kaposi's Sarcoma has been reported to occur in patients receiving corticosteriod therapy, most often for chronic conditions. Discontinuation of corticosteriods may result in clinical improvement of Kaposi's Sarcoma. Drug-Induced secondary adrenocortical insufficiency may result from too rapid withdrawal of corticosteroids and may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted, if the patient is receiving steroids already, dosage may have to be increased. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. In cerebral malaria, a double-blind trial has shown that the use of corticosteroids is associated with prolongation of coma and a higher incidence of pneumonia and gastrointestinal bleeding. Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses. Usage in Pregnancy: Since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy or in women of childbearing potential requires that the anticipated benefits be weighed against the possible hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. Corticosteroids appear in breast milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects. Mothers taking pharmacologic doses of corticosteroids should be advised not to nurse. Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. Administration of live virus vaccines, including smallpox, is contraindicated in individuals receiving immunosuppressive doses of corticosteroids. If inactivated viral or bacterial vaccines are administered to individuals receiving immunosuppressive doses of corticosteroids, the expected serum antibody response may not be obtained. However, immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison’s disease. Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients.